This is a very early head’s up.  Things are moving so fast that sometimes I have to alert you with information that might be a little bit premature.  Please take that into account as you read this alert.

This article is an editorial. My advice to you about COVID-19 vaccines, mutant strains, and “viral” therapies — along with action items to help you survive this pandemic.

We discussed Remdesivir and convalescent plasma in the previous article. In this continuation of the topic, we will discuss monoclonal antibody cocktail(s).

In this and the next article I will discuss the various therapy options presently available to us, should you get infected with COVID-19 in spite of your best efforts.

COVID-19 and immune compromised patients: I have something to say, advice that I think could be a game changer for you. How can I stay silent?

I came across several interesting bits of news – some that you can use today.  Let me know what you think.

Majority of CLL patients die of uncontrolled infections – pneumonia is the most common killer. Our guys are no strangers to secondary skin cancer either.  Immune dysfunction is baked into the CLL cake, often made worse by chemotherapy.  Anything that can improve immune function can save lives. In that context, this could easily be the most important review I have / will ever publish.

If you thought I was going to talk about the dollar cost of Rituxan, you are wrong.  Heaven knows this drug is very expensive, dollar wise.  But this article is about the hidden costs of this famous monoclonal antibody drug in terms of its not-so-well documented adverse effects.

Y’all know what FCR stands for: fludarabine, cyclophosphamide, Rituxan.  If we substitute Campath instead of Rituxan, we get a new combination – FCC.  This ASH2010 report describes (scary) clinical trial results of this combination in high risk and relapsed patients.

Have you ever thought about what you can do to improve your working relationship with your healthcare team?  It is a two way street, the mutual respect that is necessary for best outcome.